Shenzhen Beike Biotechnology Co. Ltd. has reached an investment agreement with Biomaster Inc., a Japanese company focused on the use of adipose-based stem cells for plastic surgeries. Beike and two investment companies will own a “significant” share of Biomaster, which will employ the new capital to position itself for an IPO. Financial details were not disclosed. At the same time, Beike will gain access to Biomaster’s technology, which Beike will use in its own clinics in China, Southeast Asia and South America. More details...